Henny C, Bückert A, Schutz Y, Jéquier E, Felber J P
Department of Internal Medecine, CHUV, Lausanne, Switzerland.
Int J Obes. 1988;12(3):227-36.
In a previous study, we demonstrated that the new beta-adrenoceptor agonist Ro 16-8714 possesses thermogenic property in normal male volunteers. The aim of the present study was to compare the metabolic response of lean vs obese individuals to a similar dose of this compound. Following an overnight fast, Ro 16-8714 (0.17 mg/kg fat free mass) or a placebo was given per os to six normal-weight subjects and to six moderately obese subjects. The rate of energy expenditure (EE) and the substrate utilization were determined by indirect calorimetry (hood system) before and for 6 h following the drug administration. Heart rate and blood pressure as well as plasma glucose, insulin and free fatty acid (FFA) concentrations were also measured at regular intervals throughout the study. The increment relative to base-line (mean +/- s.e.m.) in EE was similar in the two groups and averaged 4.0 +/- 1.4 per cent and 12.2 +/- 1.4 per cent with placebo and with Ro 16-8714 respectively in lean subjects, whereas the values reached 3.5 +/- 1.2 per cent and 14.4 +/- 2.0 per cent in obese subjects. Heart rate, systolic blood pressure, insulin and FFA were increased without any significant difference between the two groups. This study shows that Ro 16-8714 is a potent thermogenic agent both in normal and obese subjects.
在之前的一项研究中,我们证明了新型β-肾上腺素能受体激动剂Ro 16-8714在正常男性志愿者中具有产热特性。本研究的目的是比较瘦人和肥胖个体对相似剂量该化合物的代谢反应。在禁食过夜后,给6名正常体重受试者和6名中度肥胖受试者口服Ro 16-8714(0.17mg/kg去脂体重)或安慰剂。在给药前及给药后6小时,通过间接测热法(头罩系统)测定能量消耗(EE)率和底物利用情况。在整个研究过程中,还定期测量心率、血压以及血浆葡萄糖、胰岛素和游离脂肪酸(FFA)浓度。两组中相对于基线(平均值±标准误)的EE增加值相似,在瘦人受试者中,服用安慰剂和Ro 16-8714时分别平均为4.0±1.4%和12.2±1.4%,而在肥胖受试者中,该值分别达到3.5±1.2%和14.4±2.0%。心率、收缩压、胰岛素和FFA均升高,两组之间无显著差异。这项研究表明,Ro 16-8714在正常人和肥胖受试者中都是一种有效的产热剂。